Actinium Pharmaceuticals Unveils New Findings Showcasing Strong and Lasting Effectiveness of ATNM-400, a Pioneering Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 24 2025
0mins
Source: Newsfilter
ATNM-400 Overview: Actinium Pharmaceuticals' ATNM-400 is a first-in-class antibody radioconjugate targeting a non-PSMA antigen, demonstrating potent anti-tumor activity and prolonged survival in prostate cancer models resistant to standard therapies like enzalutamide and 177Lu-PSMA-617.
Efficacy and Resistance: Preclinical studies show that ATNM-400 outperforms existing treatments, achieving durable tumor control and complete regression in 40% of cases when combined with enzalutamide, highlighting its potential in overcoming treatment resistance.
Clinical Implications: The novel mechanism of ATNM-400 offers a promising alternative for patients with metastatic castration-resistant prostate cancer (mCRPC) who have limited options due to low or absent PSMA expression, addressing a significant unmet clinical need.
Future Directions: Actinium plans to explore ATNM-400's applications beyond prostate cancer, including non-small cell lung cancer (NSCLC), where it has shown potential to overcome resistance to existing therapies, further expanding its therapeutic impact.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATNM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATNM
Wall Street analysts forecast ATNM stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.020
Low
4.00
Averages
6.00
High
9.00
Current: 1.020
Low
4.00
Averages
6.00
High
9.00
No data
About ATNM
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ATNM-400 Demonstrates Potent Efficacy in Prostate Cancer
- Efficacy Breakthrough: ATNM-400 maintains potent activity against prostate cancer cells and tumors resistant to all three approved ARPIs, achieving a 94% tumor growth inhibition rate, significantly outperforming apalutamide and darolutamide, indicating its potential as both a monotherapy and in combination treatments.
- Safety Advantages: ATNM-400 demonstrates a consistent safety profile across both single and repeat dosing regimens with minimal off-target toxicity, showcasing good dosing flexibility and a wide therapeutic window that could mitigate clinical translation risks.
- Market Opportunity: With approximately 50,000 patients exhausting ARPI therapy annually, ATNM-400's unique mechanism positions it to address a broad patient population, from those who have failed ARPIs to PSMA-low and PSMA-negative patients, potentially serving over 100,000 patients each year.
- Preclinical Research Support: In low-PSMA expressing tumor models, ATNM-400's single bolus dosing shows superior tumor control compared to 177Lu-PSMA-617, and its target not being expressed in salivary glands suggests it will not cause xerostomia, making it a more attractive treatment option.
See More
Actinium Secures Two Patent Allowances in Canada
- Patent Protection Expansion: Actinium Pharmaceuticals has secured two patent allowances in Canada for its Actimab-A and Iomab-ACT programs, enhancing its intellectual property protection in hematologic malignancies and gene-edited cell therapies, reflecting the company's strategic positioning in global markets.
- Market Significance: This allowance not only complements existing protections in Japan and the U.S. but also establishes a foundation for growth in Canada, expected to bolster its competitive edge within a global patent estate of approximately 250 patents.
- Therapeutic Innovation: The patent for Actimab-A covers its use in combination with the CLAG-M chemotherapy regimen, anticipated to serve as a key therapeutic backbone for acute myeloid leukemia (AML) treatment, with a patent term extending to 2039, indicating long-term market potential.
- Cell Therapy Preparation: The Iomab-ACT patent focuses on preparing patients for gene-edited cell therapies, expected to drive innovation in the cell therapy space, with a patent term lasting until 2038, further solidifying its position in emerging treatment methodologies.
See More
SLS and ATNM Present Key Data Catalysts Ahead of AACR Summit
- Optimistic Outlook for SLS009: Sellas is set to present preclinical AML data on SLS009 at the AACR meeting, demonstrating significant increases in cancer cell death in models with ASXL1 and TP53 mutations, which could attract investor attention and drive stock price appreciation.
- ATNM Data Highlights: Actinium will showcase new data from its Actinium-225 radiotherapy platform at AACR, particularly regarding ATNM-400 and Actimab-A across leukemia and solid tumor programs, potentially boosting market confidence in its treatment options.
- Analyst Target Discrepancies: According to consensus estimates from Koyfin, ATNM has a 12-month average analyst price target of $5.75, implying a 342% upside, while SLS's target is $8.67, suggesting about 66% upside, indicating a higher appeal for ATNM among investors.
- Retail Sentiment Comparison: On Stocktwits, retail sentiment for ATNM is deemed 'extremely bullish', while SLS appears 'bearish', which may influence investor decisions and market performance.
See More
Actinium Pharmaceuticals Unveils Promising Data for ATNM-400 and Actimab-A
- Data Presentation: Actinium Pharmaceuticals will present new data for ATNM-400 and Actimab-A at the 2026 AACR Annual Meeting, highlighting their broad efficacy across multiple solid tumor models, which could potentially redefine current treatment standards.
- ATNM-400 Potential: As a first-in-class Ac-225 radioconjugate, ATNM-400 demonstrates the ability to combat various tumors, particularly those resistant to existing targeted therapies, positioning it as a leading treatment option for large solid tumor indications.
- Actimab-A Mechanism Innovation: Actimab-A's newly identified mechanism enhances responses to standard acute myeloid leukemia (AML) therapies through transcriptional reprogramming, showcasing its mutation-agnostic efficacy and offering new treatment options for AML patients.
- Future Outlook: Multiple data catalysts for ATNM-400 and Actimab-A are expected in 2026, with Actinium's strategy focused on continuous innovation and a diversified product pipeline, which is anticipated to drive significant value opportunities for the company.
See More
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
FibroBiologics (FBLG) Stock Rises 7.68%, Attracts Market Attention
- FibroBiologics Outperformance: FibroBiologics, Inc. (FBLG) surged 7.68% in after-hours trading to close at $0.41, indicating speculative interest or technical momentum despite no specific news.
- Nyxoah Earnings Boost Confidence: Nyxoah SA (NYXH) advanced 3.94% to $5.28 after reporting preliminary Q4 and full-year 2025 results, with guidance for Q1 2026 enhancing investor confidence in its growth trajectory.
- Fortress Biotech's Continued Volatility: Fortress Biotech, Inc. (FBIO) climbed 6.90% to $4.49 in after-hours trading, continuing a trend of volatility without any fresh news impacting the stock.
- Revvity Collaboration Drives Growth: Revvity, Inc. (RVTY) posted a 4.92% gain to close at $109.00, as investors digest the January announcement of a collaboration with Eli Lilly to expand access to predictive models via the Revvity Signals platform.
See More
ATNM-400 Demonstrates Potent Efficacy in Prostate Cancer
- Efficacy Breakthrough: ATNM-400 maintains potent activity against prostate cancer cells and tumors resistant to all three approved ARPIs, achieving a 94% tumor growth inhibition rate, significantly outperforming apalutamide and darolutamide, indicating its potential as both a monotherapy and in combination treatments.
- Safety Advantages: ATNM-400 demonstrates a consistent safety profile across both single and repeat dosing regimens with minimal off-target toxicity, showcasing good dosing flexibility and a wide therapeutic window that could mitigate clinical translation risks.
- Market Opportunity: With approximately 50,000 patients exhausting ARPI therapy annually, ATNM-400's unique mechanism positions it to address a broad patient population, from those who have failed ARPIs to PSMA-low and PSMA-negative patients, potentially serving over 100,000 patients each year.
- Preclinical Research Support: In low-PSMA expressing tumor models, ATNM-400's single bolus dosing shows superior tumor control compared to 177Lu-PSMA-617, and its target not being expressed in salivary glands suggests it will not cause xerostomia, making it a more attractive treatment option.
See More
Actinium Secures Two Patent Allowances in Canada
- Patent Protection Expansion: Actinium Pharmaceuticals has secured two patent allowances in Canada for its Actimab-A and Iomab-ACT programs, enhancing its intellectual property protection in hematologic malignancies and gene-edited cell therapies, reflecting the company's strategic positioning in global markets.
- Market Significance: This allowance not only complements existing protections in Japan and the U.S. but also establishes a foundation for growth in Canada, expected to bolster its competitive edge within a global patent estate of approximately 250 patents.
- Therapeutic Innovation: The patent for Actimab-A covers its use in combination with the CLAG-M chemotherapy regimen, anticipated to serve as a key therapeutic backbone for acute myeloid leukemia (AML) treatment, with a patent term extending to 2039, indicating long-term market potential.
- Cell Therapy Preparation: The Iomab-ACT patent focuses on preparing patients for gene-edited cell therapies, expected to drive innovation in the cell therapy space, with a patent term lasting until 2038, further solidifying its position in emerging treatment methodologies.
See More
SLS and ATNM Present Key Data Catalysts Ahead of AACR Summit
- Optimistic Outlook for SLS009: Sellas is set to present preclinical AML data on SLS009 at the AACR meeting, demonstrating significant increases in cancer cell death in models with ASXL1 and TP53 mutations, which could attract investor attention and drive stock price appreciation.
- ATNM Data Highlights: Actinium will showcase new data from its Actinium-225 radiotherapy platform at AACR, particularly regarding ATNM-400 and Actimab-A across leukemia and solid tumor programs, potentially boosting market confidence in its treatment options.
- Analyst Target Discrepancies: According to consensus estimates from Koyfin, ATNM has a 12-month average analyst price target of $5.75, implying a 342% upside, while SLS's target is $8.67, suggesting about 66% upside, indicating a higher appeal for ATNM among investors.
- Retail Sentiment Comparison: On Stocktwits, retail sentiment for ATNM is deemed 'extremely bullish', while SLS appears 'bearish', which may influence investor decisions and market performance.
See More
Actinium Pharmaceuticals Unveils Promising Data for ATNM-400 and Actimab-A
- Data Presentation: Actinium Pharmaceuticals will present new data for ATNM-400 and Actimab-A at the 2026 AACR Annual Meeting, highlighting their broad efficacy across multiple solid tumor models, which could potentially redefine current treatment standards.
- ATNM-400 Potential: As a first-in-class Ac-225 radioconjugate, ATNM-400 demonstrates the ability to combat various tumors, particularly those resistant to existing targeted therapies, positioning it as a leading treatment option for large solid tumor indications.
- Actimab-A Mechanism Innovation: Actimab-A's newly identified mechanism enhances responses to standard acute myeloid leukemia (AML) therapies through transcriptional reprogramming, showcasing its mutation-agnostic efficacy and offering new treatment options for AML patients.
- Future Outlook: Multiple data catalysts for ATNM-400 and Actimab-A are expected in 2026, with Actinium's strategy focused on continuous innovation and a diversified product pipeline, which is anticipated to drive significant value opportunities for the company.
See More
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
FibroBiologics (FBLG) Stock Rises 7.68%, Attracts Market Attention
- FibroBiologics Outperformance: FibroBiologics, Inc. (FBLG) surged 7.68% in after-hours trading to close at $0.41, indicating speculative interest or technical momentum despite no specific news.
- Nyxoah Earnings Boost Confidence: Nyxoah SA (NYXH) advanced 3.94% to $5.28 after reporting preliminary Q4 and full-year 2025 results, with guidance for Q1 2026 enhancing investor confidence in its growth trajectory.
- Fortress Biotech's Continued Volatility: Fortress Biotech, Inc. (FBIO) climbed 6.90% to $4.49 in after-hours trading, continuing a trend of volatility without any fresh news impacting the stock.
- Revvity Collaboration Drives Growth: Revvity, Inc. (RVTY) posted a 4.92% gain to close at $109.00, as investors digest the January announcement of a collaboration with Eli Lilly to expand access to predictive models via the Revvity Signals platform.
See More
